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ABSTRACT
Increasing numbers of atypical hip fractures have been reported among patients with bisphosphonate use. However, the nature and
extent of the problem are unknown despite recent investigations. To analyze national trends in hip fractures and medication use in the
elderly US population, we respectively used the Nationwide Inpatient Sample (NIS) and the Medical Expenditure Panel Survey (MEPS)
from 1996 to 2007. In NIS, subtrochanteric fragility fractures were compared with typical hip fractures in femoral neck and
intertrochanteric regions. Between 1996 and 2007, age-adjusted rates for typical hip fractures decreased by 31.6% among women
(from 1020.5 to 697.4 per 100,000 population) and 20.5% among men (from 424.9 to 337.6 per 100,000 population). In contrast, overall
trends in age-adjusted rates for subtrochanteric fragility fractures remained unchanged among men (p¼.34) but increased 20.4%
among women from 28.4 (95% confidence interval [CI] 27.7–29.1) in 1999 to 34.2 (95% CI 33.4–34.9) per 100,000 population in 2007. The
annual percentage increase was 2.1% (95% CI 1.3–2.8, p<.001) based on joinpoint regression analysis. In MEPS, bisphosphonate use
increased predominantly in women (from 3.5% in 1996 to 16.6% in 2007) compared with men (2.3% in 2007). In the context of declining
typical hip fractures among the US elderly, we observed small but significant increases in the incidence of subtrochanteric fragility
fracturesfrom1999amongpostmenopausal women.Using age-adjustedrates, weestimated thatforevery100orsoreduction intypical
femoral neck or intertrochanteric fractures, there was an increase of one subtrochanteric fragility fracture.  2011 American Society for
Bone and Mineral Research.
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Introduction
I
n the United States, there are approximately 320,000 people
hospitalized for hip fractures each year,
(1) with a 20% mortality
rate in the following year.
(2) Hip fractures occur mostly in women
over 60 years of age who were at risk of developing osteoporosis
after menopause. Osteoporosis is characterized as an increased
skeletal fragility and microarchitectural deterioration in the
bones.
(3) Prevention and treatment of osteoporosis are effective
ways to prevent hip fractures. Since 1996 after Food and Drug
Administration (FDA) approval, bisphosphonates have been
prescribed increasingly to those diagnosed with osteoporosis.
(4)
Coincident with increased use of bisphosphonates, declines in
the rates of hip fractures were observed in Canada
(5) and the
United States.
(6)
Hip fractures typically occur in the femoral neck and
intertrochanteric regions but infrequently in subtrochanteric
region.
(7) Recently, an increasing number of clinical reports
suggested an association of atypical hip fractures in subtro-
chanteric and diaphyseal regions with long-term use of
bisphosphonates,
(8–17) possibly owing to prolonged suppression
of bone turnover.
(9,18) However, post-hoc analyses of clinical trial
data
(19) and a cohort study
(20) provided counterevidence. Since
these atypical hip fractures are very rare, epidemiologic studies
with national-level data seem to be the only data source with
enough study power. Indeed, a recent epidemiologic study
showed that between 1996 and 2006, the incidence of femur
fractures distal to the lesser trochanter remained stable, whereas
more proximal hip fractures declined.
(21)
In this trend study, we analyzed prevalence in national
use of fracture-related medicines in nationally representative
surveys while evaluating trends in incidence and total estimates
of hip fractures in nationwide inpatient samples during 1996–
2007.
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553Materials and Methods
Data sources and samples
The Nationwide Inpatient Sample (NIS) is a nationally repre-
sentative all-payer inpatient database developed from the
Healthcare Cost and Utilization Project (HCUP) by the Agency for
Healthcare Research and Quality (AHRQ) and collected annually
as a stratified sample from 20% US nonfederal community
hospitals. It contains more than 6 million deidentified hospital
discharges each year, with the first of up to 15 diagnoses or
procedure codes listed as the principal reason for hospitalization
or primary procedure incurred, respectively. It also has patient
demographic information, with race as self-reported, and
hospital characteristic and facility charges related to inpatient
stays. We used NIS supplemental trend files, if necessary, which
allow accurate comparison from year to year and adjust for
changes insampling frames. Weselecteddata from 1996to2007
to evaluate the trends in hospitalizations for hip fractures.
Numbers of annual discharges were weighted to generate
national estimates for each year. It should be mentioned that
medication use was not captured in NIS. Comorbidity category
and index were generated with AHRQ software.
(22)
The Medical Expenditure Panel Survey (MEPS) is a series of
annual large-scale surveys of the civilian noninstitutionalized
population across the United States. Its main household
component (HC) collects data from a nationally representative
subsample of households that participated in the prior year’s
National Health Interview Survey (conducted by the National
Center for Health Statistics). The MEPS contains information
about respondents’ demographics, insurance status, and health
care utilization, including prescription drug use. The MEPS uses
both household interviews and pharmacy surveys for its
prescribed medicine files. We studied national utilization of
medications with bone effects such as bisphosphonates,
(19)
glucocorticoids,
(23) proton-pump inhibitors,
(24) statins,
(25,26) and
beta blockers.
(27)
Because the data used were publicly available and contained
only deidentified information, the study was exempted by the
institutional review boards at NIH, and AHRQ granted the use of
NIS and MEPS data.
Outcome measures
Hip fractures require hospitalizations and surgical interventions,
which are captured in NIS data with the International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes. We excluded open hip fractures because
they are more related to trauma or high-energy impact. After
excluding these open hip fractures, closed hip fractures
constitute more than 99.5% of all hospitalizations for hip
fractures and are likely to be osteoporotic in nature. We defined
typical hip fractures as hospitalizations with a primary diagnosis
of closed femoral neck fractures (ICD-9-CM 820.00, 820.01,
820.02, 820.03, 820.09, and 820.8) or closed intertrochanteric
fractures (ICD-9-CM 820.21) and subtrochanteric fragility frac-
tures as hospitalizations with a primary diagnosis of closed
subtrochanteric fractures (ICD-9-CM 820.22). Furthermore, we
limited the records to those with a concurrent primary ICD-9-CM
procedure code forprimary surgical treatment(7855, 7905, 7915,
7925, 7935, 7945, 7955, 7965, 7975, 7985, and 7995) or
replacement (0074, 0075, 0076, 0077, 0085, 0086, 0087, 8151,
8152, and 8169). In this way, we captured over 90% of original
records and estimated incidences of hip fractures and excluded
discharges for follow-up visits, procedures for periprosthetic
fractures, and revision procedures.
We abstracted data on annual discharge records pertaining to
specific types of hip fractures for patients aged 65 years and
older, excluding those with missing data on gender (<0.01%).
Secondary outcomes included age-standardized proportion of
specific hip fractures among total hip fractures from NIS data
and percentage of respondents with at least one prescription
medication from MEPS.
Data analysis
To calculate annual hospitalization rates, we used weighted
frequencies of hip fractures as the numerator and annual
midyear Census population estimates for the older adult
population 65 years of age and older as the denominator,
and trends in hip fracture rates were stratified by gender and
adjusted to the 1996 population in 5-year age groups (65 to 69,
70 to 74, 75 to 79, 80 to 84, and 85þ years old). Standard errors
were calculated along with age standardization.
(28) For calcula-
tion of the proportion of subtrochanteric hip fractures among all
hip fractures, the denominator was the total number of hip
fractures with ICD-9-CM¼820.X and related primary procedures
for hip replacement or treatment. For the analysis of linear
trends, we used joinpoint regression analysis to identify
significant change over time in the linear regression of the
trends in hip fracture rates (Joinpoint Regression Program,
Version 3.4.2, October 2009; Statistical Research and Applications
Branch, National Cancer Institute, Bethesda, MD, USA). Joinpoint
regression analysis enables us to test whether an apparent
change in trend or proportion was statistically significant using a
Monte Carlo permutation method and estimated variance for
each data point.
(29)
We used SAS 9.2 (SAS Institute, Inc., Cary, NC, USA) and
SUDAAN 10 (Research Triangle Institute, Research Triangle Park,
NC,USA).Allestimatesoffractureproportionandmedicationuse
took into consideration the stratified survey design of both NIS
and MEPS. To compare national estimates and demographics, a z
test and chi-square test were used, respectively. Statistical tests
were performed at two-sided significance level .05.
Results
Table 1 shows the demographic characteristics of women and
men over 65 years of age who were hospitalized with
subtrochanteric and other hip fractures from 1996 to 2007.
Among women, there were 16,766 and 445,991 subtrochanteric
and typical hip fractures, respectively. In comparison, there were
5,488 and 141,031 corresponding fractures among men. Patients
with subtrochanteric fractures were significantly younger than
those with typical hip fractures, with a higher percentage of
subtrochanteric fractures in the 65- to 74-year age group. There
554 Journal of Bone and Mineral Research WANG AND BHATTACHARYYAseemed to be more patients of minority ethnicity with
subtrochanteric fractures regardless of gender. Women with
subtrochanteric fractures tended to have three or more
comorbid conditions. All patients were covered mostly by public
insurance, more likely to be white, and were admitted from the
emergency room in over 80% of patients. With all the above-
mentioned comparisons being significant, there was no
detectable difference in the geographic distribution between
the two types of fractures (p>.05).
National estimates of hip fractures
To understand the disease burden and provide the numerators
for the incidence rate, we calculated the annual national
estimates of typical and subtrochanteric hip fractures for female,
male, and total elderly populations (Fig. 1). For the total elderly
population, estimates for hip fractures decreased 11.0% from
275,151 (95% CI 262,262–288,040) in 1996 to 244,889 (95% CI
232,472–257,305) in 2007. Typical hip fractures were 12.8% less
Table 1. Patient Characteristics
No. (%) of Women No. (%) of Men
Subtrochanteric
(n¼16,766)
Typical
(n¼445,991)
Subtrochanteric
(n¼5,488)
Typical
(n¼141,031)
Age, y
65–74 2741 (16) 61549 (14) 1475 (27) 28135 (20)
75–84 6564 (39) 184498 (41) 2366 (43) 62654 (44)
85þ 7461 (45) 199944 (45) 1647 (30) 51242 (36)
Race
White 11263 (67) 307099 (69) 3652 (67) 96859 (68)
Black, Hispanic, Pacific Islander, or Asian 1457 (8) 31360 (7) 522 (9) 11666 (8)
Unknown 4046 (24) 107532 (24) 1314 (24) 33506 (24)
Comorbid diseases
Congestive heart failure 2872 (17) 71859 (16) 989 (18) 26569 (19)
Chronic pulmonary disease 2779 (17) 79425 (18) 1337 (24) 38127 (27)
Diabetes 3231 (19) 68543 (15) 1261(23) 27058 (19)
Renal Failure 610 (4) 13079 (3) 345 (6) 9927 (7)
Rheumatoid arthritis 324 (2) 8969 (2) 52 (1) 1676 (1)
Depression 1221 (7) 35839 (8) 217 (4) 7992 (6)
No. of comorbidities
0 1515 (9) 45262 (10) 593 (11) 13333 (9)
1 3749 (22) 105183 (24) 1280 (23) 31285 (22)
2 4481 (27) 124820 (28) 1460 (27) 38321 (27)
>¼3 7021 (42) 170726 (38) 2155 (39) 59092 (42)
Admission Type
Emergency 14299 (85) 376212 (84) 4674 118253 (83)
Other 981 (6) 32544 (7) 302 10675 (8)
Unknown 1486 (9) 37235 (8) 512 13103 (9)
Primary Payer
Medicare 15259 (91) 408669 (92) 4774 127915 (90)
Medicaid 181 (1) 4142 (1) 45 1163 (1)
Private 1120 (7) 27609 (6) 520 10328 (7)
Uninsured 77 (0) 2052 (0) 38 692 (0)
Other 129 (1) 3519 (1) 111 1933 (1)
Hospital type
Teaching 10637 (63) 291722 (65) 3315 92842 (65)
Nonteaching or unknown 6129 (36) 154279 (34) 2173 49189 (35)
Hospital location
Northeast 3237 (19) 86789 (19) 999 25812 (18)
Midwest 4082 (24) 107757 (24) 1293 34320 (24)
South 6467 (39) 172288 (39) 2096 54078 (38)
West 2980 (18) 79157 (18) 1100 27821 (20)
Note: Unweighted numbers are from the Nationwide Inpatient Samples 1996–2007 for patients 65 years of age or older. Characteristics are number
(percentage) and percentages may not sum to 100 because of rounding. All comparisons of baseline characteristics (except hospital location) between
subtrochanteric and typical hip fractures are significant with a p value of less than .001.
INCREASING INCIDENCE OF SUBTROCHANTERIC FRACTURES Journal of Bone and Mineral Research 555in2007(229,942,95%CI218,224–241,660)thanin1996(263,623,
95% CI 251,227–276,019) and became significantly lower since
1999. However, the number of subtrochanteric hip fractures
increased31.2%from8273(95%CI7663–8882)in1996to10,853
(95% CI 10,115–11,589) in 2007 and became significantly higher
since 2004 (p<.05).
Age-adjusted hip fracture rates
The age-adjusted hospitalization rates for hip fractures are
shown in Fig. 2. In women, hospitalization rates decreased 31.7%
(from 1020.5 to 697.4 per 100,000) for typical hip fractures. On
the other hand, for subtrochanteric hip fractures, rates increased
9.6%from 31.2 per100,000(95% CI30.4–32.0)in1996to34.2 per
100,000 (95% CI 33.4–34.9) in 2007. In men, hospitalization rates
decreased 18.4% and 20.4% for overall and typical hip fractures,
respectively, whereas those for subtrochanteric hip fractures
remained unchanged (14.5 per 100,000, 95% CI 13.9–15.1) in
1996 compared with 15.4 per 100,000 (95% CI 14.8-16.0) in 2007.
Considering the segmentalnature oflineartrends inincidence
rates, we used joinpoint regression to analyze changes in rates,
with one joinpoint that indicated a change in the linear trend
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Fig. 2. Age-adjusted rates of subtrochanteric and typical hip fractures in elderly patients aged 65 and older. Data are based on Nationwide Inpatient
Samples. Error bars indicate 95% confidence interval. Two separate regression lines were drawn through joinpoints based on the best model fit.
556 Journal of Bone and Mineral Research WANG AND BHATTACHARYYA(Fig. 2). The incidence rate for typical hip fractures among
women decreased 4.1% per year before and 2.6% per year after
the joinpoint at 2001, and among men, 4.1% and 1.4%,
respectively (Table 2). For subtrochanteric hip fractures, the
rates of decrease from 1995 to 1999 were not significant for
either women or men (p>.05). However, the annual percentage
change since 1999 in age-adjusted rate of subtrochanteric hip
fractures was significant for women (2.1%, 95% CI 1.3–2.8) but
not for men following at later joinpoint (2.4%, 95% CI –1.1–6.0,
p¼.15).
Age-standardized proportion of subtrochanteric
hip fractures
The trend of changes in proportion of subtrochanteric hip
fractures among all hipfractures also was analyzed(Fig. 3). Based
onjoinpointregression analysis,the increaseinthe proportionof
subtrochanteric hip fractures among women was significant
from 1999 to 2007 [from 2.9% (95% CI 2.7–3.1) in 1996 to 5.0%
(95% CI 4.7–5.3) in 2007, p<.001]. Among men, no significant
changes were seen (p¼.9 from 1996 to 2001 and p¼.10 from
2001 to 2007).
Medication use
From41,750respondentsaged65yearsorolderwithinMEPS,we
obtained the proportion of those who had at least one
prescription for bisphosphonates during annual surveys from
1996 to 2007 (Fig. 3). The prevalence of bisphosphonate use
significantly increased, particularly among women (from 3.5% in
1996 to 18.4% in 2006, p<.001) but less in men (up to 2.3% in
2007). The percent increases were normalized from 0% to 100%
for both bisphosphonate use and subtrochanteric hip fractures
among women (Fig. 3), indicating that the prevalence of
bisphosphonate use preceded the increase in the proportion of
subtrochanteric fractures.Incontrast,prevalenceinnationaluses
of other fracture-related medications such as glucocorticoids,
proton-pump inhibitors, statins, and beta blockers increased in
both women and men, but the difference is not significant,
except the case of statin use, which was more prevalent in men
(Supplemental Fig. S1).
Discussion
In this 12-year study of over 90 million hospital discharge
records, we took advantage of the large sample size and
nationwide sampling of NIS to estimate rare incidences of
subtrochantericfragilityfracturesintheelderlypopulation.Inthe
context of a decline in typical hip fractures in both women
and men, we found increasing trends in incidence rate and
percentage of subtrochanteric hip fractures only among women.
The incidence rates of subtrochanteric fractures in women were
twice as high as those in men, although the proportions were
similar and low (2% to 4%) in the beginning. The secular trend of
increases in both rate and proportion were significant in women
but not in men, suggesting that elderly women bear increased
burdens ofsuch rare fractures not only inabsolute terms butalso
relative to overall hip fractures. Furthermore, these trends since
1999 were preceded by an increase in prevalence of bisphos-
phonate use among women since 1996. On the other hand,
national uses of other fracture-related medications were similar
between men and women.
These findings suggest that the case reports of more than 54
atypical hip fractures in the United States since 2005 may be not
anecdotal but rather reflective of systemic changes in the nature
of hip fractures. This is in agreement with a recent case-control
study confirming the association between atypical hip fractures
and bisphosphonate use.
(30) However, this is contradictory to
recent reports from post-hoc analyses of clinical trial data
(19) and
a cohort study.
(20) In both studies, no significant differences were
found between typical and subtrochanteric or diaphyseal hip
fractures.
Interestingly, in the study by Black and colleagues, point
estimates for the risk ratio of subtrochanteric and diaphyseal
fractures from three trials were all above 1.00 in the treatment
group and higher in trials with longer exposure to bisphos-
phonates or with more potent agents such as zoledronic acid. It
also should be mentioned that in the only trial where the
intertrochanteric fractures were significantly reduced (HORIZON
trial), the risk ratio of subtrochanteric and diaphyseal femur
fractures was highest in point estimates. Furthermore, while
sevensubtrochantericordiaphysealfemurfracturesintreatment
allwerefoundtoresultfromminimaltrauma(afallfromstanding
Table 2. Annual Percentage Change (APC) in Age-adjusted Rates of Hip Fractures by Sex According to Joinpoint Regression Analysis
Overall Hip Fractures Typical Hip Fractures Subtrochanteric Hip Fractures
Segments APC, %(95% CI) Segments APC, %(95% CI) Segments APC, %(95% CI)
Both Sexes 1996–2000  4.1( 5.5 to  2.6) 1996–2000  4.2( 5.7 to  2.8) 1996–1999  2.8( 7.1 to 1.7)
c
2000–2007  2.4( 3.0 to  1.7) 2000–2007  2.6( 3.4 to  2.4) 1999–2007 2.0(1.1 to 2.9)
Female 1996–2001  3.9( 5.0 to  2.9) 1996–2001  4.1( 5.1 to  3.1) 1996–1998  2.9( 12.6 to 3.7)
c
2001–2007  2.4( 3.2 to  1.5) 2001–2007  2.6( 3.4 to  1.8) 1998–2007 2.1(1.3 to 2.8)
Male 1996–1999  4.0( 6.9 to  1.0)
a 1996–1999  4.1( 6.9 to  1.2) 1996–2000  2.6( 10.7 to 6.2)
c
1999–2007  1.3( 1.9 to  0.6)
b 1999–2007  1.4( 2.1 to  0.7) 2000–2007 2.4( 1.1 to 6.0)
c
APC¼annual percentage change; CI¼confidence interval.
ap¼.017.
bp¼.003.
cp>.05. All other p values are less than .001.
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higher impact such as falls from a stair, step, or curb. Although it
is hard to discuss the significance of these findings, randomized
trials should give some indications as to the tendency of risk
changes.
In another study with population-based registry, fracture risks
for the hip and subtrochanteric or diaphyseal femur were more
common in bisphosphonate users than in nonusers.
(20) This may
be an example of confounding by indication often seen in
observational studies,
(31) given the tendency to use bisphos-
phonates in patients with osteoporosis and/or higher risk of hip
fractures. In addition, this study did not exclude fractures owing
to high-energy trauma. And finally, despite from a national
register, fewer than 200 people were determined to be highly
adherent with more than 6 years of bisphosphonate treatment.
A recent study of National Hospital Discharge Survey (NHDS)
indicates that although there was a decline in hip fracture rate,
no increase in closed subtrochanteric fractures was found.
(21)
This is not unexpected because estimates for less common
procedures and diagnoses tend to be less reliable if the sample
size is smaller than a million.
(32) NIS, on the other hand, has been
used for studying other rare medical events such as pneumonia
hospitalizations complicated by empyema in children with an
incidence rate of less than 10 per 100,000.
(33)
Our estimates of rates and declines for typical hip fractures are
consistent with earlier studies using NIS
(34) and Medicare data.
(6)
In addition to the diagnosis code, we also incorporated
procedure codes to ascertain the incidence of hip fractures
and excluded revision surgeries and follow-up visits. Our
estimates of subtrochanteric hip fractures were comparable
with those from Black and colleagues
(19) and Nieves and
colleagues,
(21,35) although they included femur shaft fractures
and had patients from 50 years and older. The reason we did not
include the shaft fractures was that we intended to study the
proportion of subtrochanteric hip fracture among all hip
fractures, and femur shaft fractures represent a different type
in that regard. On including the shaft fractures, increasing trends
ofsubtrochanteric andfemoralshaftfractureswerestillobserved
(unpublished data).
While our results are consistent with the protective effect of
bisphosphonates against typical hip fracture, we also showed a
temporal correlation between national use of bisphosphonates
and delayed increase in subtrochanteric fractures. It remains to
be seen whether the increasing incidence should occur
specifically among those with relevant medication usage. We
noted that women were the predominant users of bisphos-
phonates and experienced the vast majority of subtrochanteric
fractures. If the rise in subtrochanteric fractures were due to an
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558 Journal of Bone and Mineral Research WANG AND BHATTACHARYYAenvironmental effect, a shift in coding practices, or rising general
awareness, it would be seen in men as well.
Our study has strengths related to the national representation,
high sensitivity, and contextual analysis for different outcomes.
However, there are limitations associated with this ecologic
investigation. First, MEPS and NIS may not be representative of
the same segment of the US population such that comparing
trends in these two data sets has limitations. Second, data were
not available or shown regarding other trends in lifestyle factors
that also might explain fracture trends, such as physical activity,
use of dietary supplements, smoking, and use of other
medications such as selective estrogen receptor modulator
(SERMs), parathyroid hormone, and estrogen. And finally, the
administrative data we used are limited in that closed
subtrochanteric fracture were unspecific for those ‘‘atypical’’
fractures without knowing if such characteristic radiographic
findings were present as reported in clinical case reports.
(14,16,35)
We may have overestimated the extent of such fractures by
using ICD-9 codes rather than radiographs to identify fractures.
However, since subtrochanteric hip fracture is a very rare
outcome, claims data may be better suited to address the
problem with sufficient power. Our preliminary findings call for a
large cohort study with longitudinal data about health outcomes
and long-term medication history.
Our data may define the extent of divergence between these
two trends. National estimates of hospitalizations for hip
fractures declined by more than 30,000 between 1996 and
2007 despite aging of the population. In contrast, there were
approximately 2,500 more subtrochanteric hip fractures in 2007
than in 1996. It is obvious that the extent of increase in
subtrochanteric hip fractures remains very small compared with
the substantial declines in typical or overall hip fractures. Using
age-adjusted rates, we estimate that for every 323 reduction in
typical femoral neck or intertrochanteric fractures, there was
concurrent increase of 3 subtrochanteric fractures. Even after we
included closed femoral shaft fractures, which have been
implicated following long-term bisphosphonate therapy,
(36)
the increase in these hip fractures is still around 10 per 300
typical hip fractures reduced (unpublished data). This estimate
was similar to what Black and colleagues reported based on the
minimumvalue of hypothetical relative risk of subtrochanteric or
diaphyseal femur fractures in their clinical trial data.
We also confirmed that in the beginning of our study period,
subtrochanteric fractures constitute only 2% to 4% of all hip
fractures,
(37) a proportion of which increased significantly but
modestlyamongwomen.Thus,eventhoughincreasingtrendsof
subtrochanteric hip fractures were significant, the extent of the
problem was minor, and the potential for future increases may
be limited. However, such incidences should be monitored on
the population level and prevented, if possible, during individual
care.
In the United States, where burdens of overall hip fractures are
falling, annual national estimates and age-adjusted rates of
subtrochanteric hip fractures, albeit very low, are on the rise
among women aged 65 years and older. Although these
increasing trends were temporally correlated with prevalence in
bisphosphonate use among postmenopausal women, this study
only fulfills a temporality requirement for a possible causal
relationship between bisphosphonate use and changes in the
patterns and distribution of hip fractures.
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